DeepMed Research

Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients

Not Applicable

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Major Depression

Interventions: Behavioral: Enhanced Care
Behavioral: Treatment Adherence Intervention

First Posted Date: 2005-09-08

Last Posted Date: 2010-01-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 141

Registration Number: NCT00151372

Locations: 🇺🇸
Helen Hayes Hospital, West Haverstraw, New York, United States
🇺🇸
Weill Medical College of Cornell University, White Plains, New York, United States
🇺🇸
Burke Rehabilitation Hospital, White Plains, New York, United States

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Bortezomib, CHOP, Rituximab

First Posted Date: 2005-09-08

Last Posted Date: 2018-06-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 76

Registration Number: NCT00151320

Locations: 🇺🇸
Columbia University College of Physicians and Surgeons, New York, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: PEPC
Drug: Thalidomide
Drug: Rituximab

First Posted Date: 2005-09-08

Last Posted Date: 2018-06-28

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 25

Registration Number: NCT00151281

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis

Phase 4

Terminated

Conditions: Depression
Multiple Sclerosis

First Posted Date: 2005-09-08

Last Posted Date: 2006-09-14

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT00151294

Locations: 🇺🇸
NewYork Presbyterian Hospital, White Plains, New York, United States

Effects of Cerebral Oxygen Saturation on Neuropsychological Outcomes

Phase 2

Terminated

Conditions: Cardiovascular Diseases
Postoperative Complications

First Posted Date: 2005-09-08

Last Posted Date: 2008-06-06

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 200

Registration Number: NCT00151307

Locations: 🇺🇸
New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, United States

Combined Spinal-Epidural Versus Traditional Labor Epidural

Phase 4

Completed

Conditions: Labour Pain

Interventions: Drug: Bupivacaine and Fentanyl (for CSE)
Drug: Bupivacaine and Fentanyl (for traditional epidural)

First Posted Date: 2005-09-08

Last Posted Date: 2008-03-18

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 127

Registration Number: NCT00151346

Locations: 🇺🇸
New York-Presbyterian Hospital; Weill Medical College of Cornell, New York, New York, United States

Genotype - Phenotype Correlations of LINCL

Completed

Conditions: Late-Infantile Neuronal Ceroid Lipfuscinosis
Batten Disease

First Posted Date: 2005-09-08

Last Posted Date: 2016-07-29

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 18

Registration Number: NCT00151268

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: dexamethasone
Drug: liposomal doxorubicin
Drug: cyclophoshamide
Drug: filgrastim

First Posted Date: 2005-09-07

Last Posted Date: 2017-07-18

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 38

Registration Number: NCT00148317

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Phase 1

Completed

Conditions: HIV Infections
Body Weight Changes
HIV-Associated Lipodystrophy Syndrome
Metabolic Syndrome X
Insulin Resistance

Interventions: Drug: Rosiglitazone
Drug: Recombinant human growth hormone + rosiglitazone

First Posted Date: 2005-08-15

Last Posted Date: 2014-02-13

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 77

Registration Number: NCT00130286

Locations: 🇺🇸
Cornell HIV Clinical Trials Unit, Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
AIDS Community Research Initiative of America (ACRIA), New York, New York, United States
🇺🇸
St. Luke's-Roosevelt Hospital Center, New York, New York, United States

and more 1 locations

Psychodynamic Therapy for Treating Panic Disorder

Phase 2

Completed

Conditions: Panic Disorder

Interventions: Other: PFPP
Other: ART

First Posted Date: 2005-08-09

Last Posted Date: 2013-06-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 49

Registration Number: NCT00128388

Locations: 🇺🇸
Weill Medical College, New York City, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy